PR Center

Press Release

[Press Releases] [Press Release]Theragen Bio Achieves 1000th Run with Illumina's 'NovaSeq 6000' S4

마케팅커뮤니케이션2023-12-08Hit 539

■Pioneering a New Chapter in Genomic Research with Innovative Achievement

Global genomic analysis service and AI-based drug development company, Theragen Bio (CEO: Samuel Hwang), has recently completed its 1000th run using Illumina's NovaSeq 6000 S4 sequencer, setting yet another historic milestone as a leader in genomic analysis.

The NovaSeq 6000 boasts high performance, capable of analyzing an average of 1000 samples up to 6 terabytes within just two days, significantly enhancing the research speed and depth of scientists worldwide. Theragen Bio has dramatically reduced the time and cost of sequencing analysis with the NovaSeq 6000, greatly improving access to WGS, WGBS, WES, and RNA-Seq research. Consequently, clinical research exploring the link between genetic variation and health and disease has advanced rapidly, benefiting researchers and patients alike. This 1000th run transcends mere numbers and extends the possibilities of global genomic research.

CEO Samuel Hwang of Theragen Bio stated, "This record symbolizes the practical achievements made through constant internal innovation and repeated improvements in customer service in the genomic research and clinical market. Based on these experiences, we will continue to innovate persistently to provide higher quality services to researchers both domestically and internationally."